We therefore propose that the DAPA-mediated increase in ZAG could be caused by the activation of PPAR-γ in insulin target tissues, and this may counteract the decreased activation of PPAR-γ that occurs in response to increasing IR in T2DM patients. Here, AZGP1 is linked to type 2 diabetes mellitus.